- Report
- October 2024
- 183 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- April 2025
- 173 Pages
Global
From €4692EUR$4,950USD£3,920GBP
- Report
- July 2024
- 185 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- August 2024
- 132 Pages
North America
From €3791EUR$4,000USD£3,167GBP
- Report
- October 2023
- 120 Pages
Global
From €5640EUR$5,950USD£4,711GBP
- Report
- September 2023
- 120 Pages
North America
From €5640EUR$5,950USD£4,711GBP
- Report
- June 2021
- 120 Pages
Global
From €2370EUR$2,500USD£1,980GBP
- Report
- July 2022
- 180 Pages
Global
From €3497EUR$3,690USD£2,922GBP
The Bloodstream Infection Test market is a subset of the larger Infectious Disease Testing market. It is used to detect the presence of bacteria, fungi, and viruses in the bloodstream. The test is typically performed on a sample of blood taken from a patient, and the results are used to diagnose and treat infections. The test can also be used to monitor the effectiveness of treatments.
The Bloodstream Infection Test market is highly competitive, with a range of products available from different manufacturers. These products vary in terms of accuracy, cost, and turnaround time. The market is also subject to regulatory requirements, which can affect the availability of certain products.
Some companies in the Bloodstream Infection Test market include Abbott, Becton Dickinson, Cepheid, DiaSorin, Hologic, and Roche. Show Less Read more